1
Home
Companies

Cogent Biosciences

#5008

Rank

$1.6B

Marketcap

US United States

Country

Cogent Biosciences
Leadership team

Mr. Andrew R. Robbins M.B.A. (Pres, CEO & Director)

Dr. John Edward Robinson Ph.D. (Chief Scientific Officer)

Dr. Jessica Sachs M.D. (Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Medical, Therapeutics
Number of Employees
50 - 100
Headquarters
Cambridge, Massachusetts, United States
Established
2014
Company Registration
SEC CIK number: 0001622229
Traded as
COGT
Social Media
URL
https://www.cogentbio.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
History

Cogent Biosciences was founded in 2012 by a team of scientists and entrepreneurs with a shared belief that new medicines can be developed to effectively treat difficult-to-treat genetic diseases. Leveraging its proprietary platform, Cogent has identified and validated more than 500 single epigenetic chromatin regulator targets and a comprehensive set of predictor biomarkers for selected diseases and for applications across oncology and immuno-oncology.

Mission
Cogent Biosciences’ mission is to develop novel therapies and diagnostics that provide transformative treatments for patients with unmet medical needs.
Vision
Cogent Biosciences’ vision is for an effective, safe, and personalized medicine that is tailored to each individual’s unique genetic makeup.
Key Team

Mr. John L. Green C.A., CPA (CFO & Principal Accounting Officer)

Mr. Brad Barnett (Chief Technology Officer)

Mr. Evan D. Kearns J.D. (Chief Legal Officer & Corp. Sec.)

Ms. Erin Schellhammer (Chief People Officer)

Ms. Sara Saltzman (Sr. VP of Regulatory Affairs)

Mr. Dana R. Martin Pharm.D. (Sr. VP of Medical Affairs & Chief Patient Officer)

Brad Fell (VP & Head of Medicinal Chemistry)

Recognition and Awards
Cogent Biosciences was named one of FierceBiotech's 2019 Fierce15 winners, which recognizes the top 15 biotech companies of the year.
References

https://en.wikipedia.org/wiki/Cogent_Communications

https://in.investing.com/equities/unum-therapeutics-inc

https://www.comparably.com/companies/cogent-biosciences

https://www.crunchbase.com/organization/unum-therapeutics

https://finance.yahoo.com/quote/COGT/

https://www.cogentbio.com

https://sec.report/CIK/0001622229

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Cogent Biosciences
Leadership team

Mr. Andrew R. Robbins M.B.A. (Pres, CEO & Director)

Dr. John Edward Robinson Ph.D. (Chief Scientific Officer)

Dr. Jessica Sachs M.D. (Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Medical, Therapeutics
Number of Employees
50 - 100
Headquarters
Cambridge, Massachusetts, United States
Established
2014
Company Registration
SEC CIK number: 0001622229
Traded as
COGT
Social Media
URL
https://www.cogentbio.com